What are these two products?
1. Cagrilintide 10mg
Cagrilintide is a long-acting amylin receptor agonist.
|
Item |
Description |
|---|---|
|
Drug Class |
Long-acting amylin receptor agonist |
|
Mechanism of Action |
Mimics the amylin hormone, delays gastric emptying, increases satiety, reduces food intake |
2. Tirzepatide
Tirzepatide is a single-molecule dual receptor agonist.
|
Item |
Description |
|---|---|
|
Drug Class |
GIP + GLP-1 dual receptor agonist |
|
Mechanism of Action |
Simultaneously activates GIP and GLP-1 receptors, enhances insulin secretion, suppresses appetite, delays gastric emptying |
Detailed Data Comparison
1.Usage Steps
| Product | Usage Steps | Convenience Assessment |
|---|---|---|
| Cagrilintide 10mg | Reconstitute → Draw → Inject (3 steps) | More complex, requires additional manipulation |
| Tirzepatide | Draw → Inject (2 steps) | Simpler, ready-to-use |
Analysis:
- Cagrilintide 10mg is a lyophilized powder formulation, requiring reconstitution with the provided solvent before injection. This increases the procedure and places higher demands on the patient's manual skills (e.g., aseptic technique and dosage accuracy).
- Tirzepatide, on the other hand, is a ready-to-use solution. The solution in the vial can be directly drawn and injected, eliminating the reconstitution step. This makes it more convenient and suitable for home administration.
Conclusion: Tirzepatide has a significant advantage in ease of use.
Target
| Product | Targets | Physiological Effects |
|---|---|---|
| Cagrilintide 10mg | GLP-1 + Amylin | Appetite suppression + Increased satiety (two distinct pathways) |
| Tirzepatide | GIP + GLP-1 | Enhanced insulin secretion + Appetite suppression (synergistic effect) |
Analysis:
- GLP-1 (glucagon-like peptide-1): Delays gastric emptying, suppresses appetite, and promotes insulin secretion-both act on this classic target.
- Amylin: A hormone secreted by pancreatic β-cells, released co-with insulin, its main function is to delay gastric emptying and increase satiety.
- GIP (glucose-dependent insulinotropic peptide): Belongs to the incretin family, similar to GLP-1, it enhances postprandial insulin secretion and may regulate body weight through central effects.
Target Comparison Summary:
| Target Combination | Representative Drug | Core Advantage |
|---|---|---|
| GLP-1 + Amylin | Cagrilintide 10mg | Two complementary appetite-suppression pathways |
| GIP + GLP-1 | Tirzepatide | Dual incretin synergy, more comprehensive metabolic regulation |
Conclusion: The two drugs have different target combinations and different focuses. Current clinical data shows that the GIP+GLP-1 combination of telpolide has better weight loss effect; the GLP-1+amylin combination of Cagrilintide 10mg is a novel approach, and its long-term effects still need to be verified.
Weight loss effect (obesity)
| Product | Key Trial | Treatment Duration | Mean Weight Loss |
|---|---|---|---|
| Cagrilintide 10mg | REDEFINE 4 | 84 weeks | -23.0% |
| Tirzepatide | SURMOUNT-1 | 72 weeks | -25.5% |
Analysis:
- The weight loss rate of telpotetide was 2.5 percentage points higher than that of Cagrilintide 10mg (absolute difference).
- Based on an initial weight of 100kg, telpotetide resulted in an average weight loss of 2.5kg more.
- It should be noted that the two trials had different durations (84 weeks vs. 72 weeks), but even considering the time factor, telpotetide's weight loss advantage remains.
Conclusion: Telpotetide is slightly superior in weight loss efficacy and is currently the benchmark for weight loss efficacy among marketed drugs.
Weight loss effect (for patients with type 2 diabetes)
| Product | Key Trial | Treatment Duration | Mean Weight Loss |
|---|---|---|---|
| Cagrilintide 10mg | REIMAGINE 2 | 68 weeks | -14.2% |
| Tirzepatide | SURPASS series | 40-72 weeks | Approx. -11% ~ -13% |
Analysis:
- In individuals with type 2 diabetes, both medications showed significantly lower weight loss effects compared to obese individuals (due to the effects of diabetes itself and some hypoglycemic agents on weight).
- Cagrisema's weight loss data (-14.2%) was slightly better than the historical data range for telpotetide (-11% to -13%).
- However, it should be noted that the two were not directly compared in the same trial, and telpotetide's weight loss effect was dose-dependent (maximum effect at 15mg). Therefore, this difference is for reference only.
Conclusion: The weight loss effects of both medications in diabetic individuals are roughly equivalent, with Cagrilintide 10mg showing a slight numerical advantage, but this needs to be confirmed by head-to-head trials.
Blood sugar lowering effect (HbA1c reduction)
| Product | Key Trial | Baseline HbA1c | HbA1c Reduction |
|---|---|---|---|
| Cagrilintide 10mg | REIMAGINE 2 | 8.2% | -1.91% |
| Tirzepatide | SURPASS-2 | 8.3% | Approx. -2.0% ~ -2.3% |
Analysis:
- Tirzepatide exhibits a dose-dependent effect in lowering blood glucose, with a reduction of approximately -2.3% at the 15mg dose.
- CgriSema's -1.91% reduction is excellent, but slightly lower than the optimal dose result for telborpeptide.
- Both are significantly more potent than traditional oral hypoglycemic agents, falling into the "highly effective" category.
Conclusion: Tirzepatide is slightly superior to Cagrilintide 10mg in lowering blood glucose, with a difference of approximately 0.1-0.4 percentage points.
Common side effects
| Product | Nausea Incidence | Diarrhea Incidence | Vomiting Incidence | Overall Assessment |
|---|---|---|---|---|
| Cagrilintide 10mg | ~32% | ~20% | ~15% | Higher |
| Tirzepatide | ~25% | ~20% | ~10% | Moderate |
Analysis:
- Both had highly similar side effects, primarily gastrointestinal reactions, the vast majority of which were mild to moderate and lessened over time.
- The incidence of nausea (32% vs. 25%) and vomiting (15% vs. 10%) was slightly higher with Cagrilintide 10mg than with telpotetide, possibly related to its dual appetite-suppressing mechanism (GLP-1 + amylin).
- Telpotetide showed relatively better gastrointestinal tolerability.
Conclusion: Telpotetide has a slight advantage in gastrointestinal tolerability, while Cagrilintide 10mg has a relatively higher risk of nausea.
In summary, telpolide is slightly superior to Cagrilintide 10mg, which is currently in clinical trials, in terms of both weight loss efficacy and ease of use. Cagrilintide 10mg's value lies in its unique "GLP-1 + amylin" mechanism, offering a new treatment option for the future.
Quality guaranteed, stock ready, place your order now!
My email：sales4@lymallpanda.com
WhatsApp：+86 15353955739
